SummaryRMgm-95
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 18761621 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 2.34 |
Other information parent line | P. berghei ANKA 2.34 is a cloned, gametocyte producer line of the ANKA strain (PubMed: PMID: 15137943). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | A. Ecker; R.E. Sinden |
Name Group/Department | Division of Cell and Molecular Biology |
Name Institute | Imperial College |
City | London |
Country | United Kingdom |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-95 |
Principal name | ∆psop9 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal production of ookinetes. Possibly a reduced ookinete invasion and traversal of the midgut wall. |
Oocyst | Reduced numbers of oocysts: 22% of wild type (9-41%). Oocysts formed are morphologically indistinguishable from wild type oocysts. Sporozoites persist within oocysts at least until day 30 of infection, and fail to produce salivary gland infections. |
Sporozoite | Sporozoites persist within oocysts at least until day 30 of infection, and fail to produce salivary gland infections, resulting in strongly reduced numbers of salivary gland sporozoites: 0.3% of wild type (0.0-0.7%). No transmission to C57BL/6 mice by bite of infected mosquitoes. |
Liver stage | See also the phenotype of sporozoites. No transmission to C57BL/6 mice by bite of infected mosquitoes. Injection of large numbers of midgut sporozoites (500.000) into C57BL/6 mice did not result in a blood stage infection. |
Additional remarks phenotype | Mutant/mutation It has been reported that the P. falciparum ortholog, PF08_0008, is refractory to gene knockout attempts (Arumugam TU, 2011, Infect. Immun.; PMID: 21896773. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0701900 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0828800 | ||||||||||||||||||||||||
Gene product | GPI-anchored micronemal antigen | ||||||||||||||||||||||||
Gene product: Alternative name | PSOP9; putative secreted ookinete protein 9; GAMA | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |